Table 1 Characteristics of patients who were diagnosed with de novo stage IV breast cancer
From: Could local surgery improve survival in de novo stage IV breast cancer?
Variable | No. Patients(N = 313) | Percentage |
|---|---|---|
Age at diagnosis | ||
≤ 50 | 189 | 39.6 |
> 50 | 124 | 60.4 |
Menopause status | ||
Menses | 193 | 61.7 |
Menopause | 115 | 36.7 |
Unknown | 5 | 1.6 |
Biopsy | ||
Mass resection | 27 | 8.6 |
Core needle | 229 | 73.2 |
Fine needle | 1 | 0.3 |
Unknown | 56 | 17.9 |
Tumor size | ||
≤ 5 cm | 174 | 55.6 |
> 5 cm | 120 | 38.3 |
Unknown | 19 | 6.1 |
Lymph node involvement | ||
N0 | 28 | 8.9 |
N1 | 44 | 14.1 |
N2 | 71 | 22.7 |
N3 | 129 | 41.2 |
Unknown | 41 | 13.1 |
Hormone receptor status | ||
+ | 212 | 67.7 |
- | 94 | 30.0 |
Unknown | 7 | 2.2 |
HER2 receptor status | ||
Amplified | 132 | 42.2 |
No-amplified | 161 | 51.4 |
Not known or equivocal(2+) | 20 | 6.4 |
Molecular subtype | ||
Luminal A | 55 | 17.6 |
Luminal B | 141 | 45.0 |
HER2 | 56 | 17.9 |
Triple negative | 33 | 10.5 |
Unknown* | 28 | 8.9 |
Surgery | ||
Yes | 188 | 60.1 |
No | 125 | 39.9 |
Type of surgery | ||
Modified radical mastectomy | 181 | 96.3 |
Lumpectomy | 3 | 1 |
Simple mastectomy | 4 | 1.3 |
Margin status | ||
Negative | 184 | 97.9 |
Positive | 4 | 2.1 |
Endocrine therapy$ | ||
Yes | 123 | 39.3 |
No | 190 | 60.7 |
Anti-HER2 therapy$ | ||
Yes | 71 | 22.7 |
No | 239 | 76.4 |
Unknown | 3 | 1 |
Chemotherapy(first line regimen)$ | ||
CAF/CEF | 9 | 2.9 |
Taxane based/taxane +anthracyline | 241 | 77.0 |
Platinum based | 17 | 5.4 |
Others | 20 | 6.4 |
Unknown | 26 | 8.3 |
Bisphosphonate | ||
Yes | 92 | 29.4 |
No | 221 | 70.6 |
OFS* | ||
Yes | 58 | 18.5 |
No | 255 | 81.5 |
Radiotherapy | ||
Yes | 99 | 31.6 |
No | 184 | 58.8 |
Unknown | 30 | 9.6 |
Viscera metastasis | ||
Yes | 167 | 53.4 |
No | 146 | 46.6 |
Bone metastasis | ||
Yes | 171 | 54.6 |
No | 142 | 45.4 |
CNS metastasis* | ||
Yes | 11 | 3.5 |
No | 302 | 96.5 |
Soft tissue metastasis | ||
Yes | 139 | 44.4 |
No | 174 | 55.6 |
No. of metastasis sites | ||
≤ 3 | 288 | 92.0 |
> 3 | 25 | 8.0 |
Overall survival(months) | ||
Median | 62 | – |
95% Confidence interval | 45.79–78.21 | – |